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Abstract Habitual smoking of marijuana is associated with
multiple respiratory symptoms such as cough, sputum pro-
duction, and wheezing .These symptoms are not significantly
different from those exhibited by tobacco smokers. Further-
more, endobronchial biopsies of habitual smokers of marijua-
na and /or tobacco have shown that both marijuana and
cigarette smoking cause significant bronchial mucosal histo-
pathology and that these effects are additive. Although mari-
juana smokers have minimal changes in pulmonary function
studies as compared to tobacco smokers, they may develop
bullous disease and spontaneous pneumothoraces. The rela-
tionship between marijuana smoking and lung cancer remains
unclear due to design limitations of the studies published so
far. These findings should warn individuals that marijuana
smoking may result in serious short-term and long-term respi-
ratory complications, and habitual marijuana use should be
viewed with caution. The medical literature so far does not
support routine evaluation by pulmonary function tests or
imaging studies; until more definitive data is available, we
do not recommend the regular use of these tests in the evalu-
ation of habitual marijuana smokers.
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Introduction
In 2012, an estimated 23.9million Americans aged 12 or older
were current illicit drug users. Marijuana (cannabis) was the
most commonly used drug, with 18.9 million users, an in-
crease from 14.5million between 2007 and 2012 [1]. As drug-
related laws evolved with the enactment of Colorado’s
Amendment 64 and the similar Washington Initiative 502,
the legalization of marijuana has increased accessibility to a
drug whose principle route of administration is via inhalation.
Therefore, knowledge of the pulmonary complications of
marijuana use is relevant to current medical practice.
Historically marijuana use dates back as far as 2700 BC
China with a variety of roles ranging from textiles to medic-
inal use [2]. Medical indications for cannabis included rheu-
matic pain, intestinal constipation, disorders of the female
reproductive system, malaria, and others [3] . The medical
use of cannabis spread from Europe to the Americas much
later with culmination of use in the second half of the 19th
century [2] . By this time over 100 articles had been published
on the therapeutic indications of marijuana [4] with different
laboratories including Merck (Germany), Burroughs-
Wellcome (England), Bristol-Meyers Squibb (United States),
Parke-Davis (United States), and Eli Lilly (United States)
marketing tincture of cannabis [5] . However there was a
decline in its use in medical practice in the 20th century and
it was removed from the American pharmacopoeia in 1941[6].
Marijuana is derived from the Cannabis sativa plant and the
active ingredients known as “cannabinoids” are found within
the stalks, leaves, flowers, and seeds of the plant [7]. The drug
is prepared using the dried flower tops and leaves. The major
psychoactive agent in marijuana is 1-δelta-9-tetra
hydrocannabinol (THC) with additional cannabinoid-like
compounds and tar components similar to tobacco smoke
[8]. However, more than 400 compounds have been identified
in marijuana, including 60 different cannabinoids [9]. These
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include cannabinol (CBN), cannabidiol (CBD), and delta-8-
tetra hydrocannabinol, which do not produce significant psy-
choactive effects [7]. The average cannabinoid content in
dried marijuana leaves in the United States between 1993
and 2008 was 4.5 % THC, 0.4 % CBD, and 0.3 % CBN
[10]. Hashish, which is a more concentrated form, was noted
to have a higher THC concentration (14.1 % THC, 2.4 %
CBD, and 1.9 % CBN) [10]. The THC content and potency of
marijuana joints have increased when compared to the 1960s
and 1970s. In the 1960s the average THC content of a joint
was 10mg [9]. In current rolled cigarettes this has increased to
150 mg and up to 300 mg if hashish oil is added [9]. Potency
of THC in marijuana samples has steadily increased from 3 %
in 1980 to 12 % in 2012, raising the concern that the conse-
quences of marijuana use may be worse now than reported in
past literature.
Marijuana and the airways
Several reports in the last few years have indicated that inhaled
marijuana may, in fact, dilate the airways of healthy and
asthmatic individuals, an effect that lasts only a few minutes
to hours. However, THC, which is known to act as a short-
term bronchodilator, also has long-term biological effects.
These effects may cause structural and functional changes in
the lung parenchyma and airways.
Habitual marijuana smokers report a wide range of symp-
toms such as cough, dyspnea, sputum production, wheezing,
pharyngitis, hoarseness of voice, and worsening of asthma
symptoms [11] . The symptoms are comparable to the symp-
toms exhibited by tobacco smokers who have smoked for at
least 10 years. Tashkin et al. assessed the respiratory function
in seventy-four habitual marijuana smokers and a matched
group of controls. Fifty of the seventy-four subjects had never
smoked tobacco or had not smoked tobacco for 6 months. The
researchers noted that among marijuana smokers and/or to-
bacco users, the prevalence of chronic cough was 18 to 24 %;
sputum production was 20 to 26 %, and wheeze was 25 to
37 %, with at least two prolonged episodes of acute bronchitis
during the previous 3 years (10–14 %), significantly higher
than among the non-smokers (p <0.05). Nonetheless, there
was no difference in the prevalence of chronic cough, sputum
production, or wheeze between the marijuana and tobacco
smokers or combined smokers of both marijuana and tobacco
[12].
Spirometric evaluation of lung function demonstrated an
increased airflow resistance in young habitual smokers of
marijuana [12] . Furthermore, a study by Aldington et al.
included subjects who smoked both marijuana and tobacco
in addition to those smoking marijuana or tobacco alone[13].
Nonsmokers represented the control group. 339 patients
returned a respiratory and smoking questionnaire and
underwent pulmonary function testing in addition to HRCT.
The authors found a dose–response relationship between can-
nabis smoking and decreased FEV1/FVC ratio, increased
specific airway conductance, and increased total lung capac-
ity. The lung density on HRCT was decreased with macro-
scopic emphysema in 16.3 % of the combined group and
1.3 % in the cannabis-only group.
The results of the study by Tashkin raised the possibility of
histologic changes in the mucosa of the central airways which
might be qualitatively similar to the changes present in the
mucosa of tobacco smokers [12]. Airway histology was stud-
ied by Fligiel et al. in habitual smokers of cocaine, marijuana,
and tobacco by using bronchoscopy and endobronchial biop-
sies [14]. The authors found that both smokers of marijuana
and cigarettes had significant bronchial mucosal abnormalities
and that these effects were additive. They reported that 20–
26% of young smokers ofmarijuana and/or tobacco displayed
some symptoms of chronic bronchitis and as many as 80 %
had evidence of cellular atypia and mucosal metaplasia in the
major bronchi.
The same group also assessed early effects of marijuana
and tobacco smoking on the airway mucosa using a visual
bronchitis index assessed by bronchoscopy and transbronchial
biopsies [15]. The bronchitis index was defined as vascular
proliferation, edema, cellular infiltrates, and goblet cell hyper-
plasia. The average screening spirometry was normal in all
subjects. Both marijuana and tobacco smoking were associat-
ed with visual evidence of central airway inflammation in the
majority of subjects. All biopsies from subjects smoking
marijuana, tobacco, or both were graded as abnormal. Muco-
sal erythema was present in 95 % of samples, with three of the
four bronchial index criteria present in 72 % of subjects and
48 % of subjects fulfilling all four. The IL-8 concentration in
the BAL correlated with the BAL neutrophil counts, and both
were significantly increased in smokers of both marijuana as
well as tobacco.
A cohort study byHancox et al. evaluated the lung function
in 1,037 individuals with 71.6 % of subjects having smoked
marijuana at least once in their lifetime [16]. In this study
cumulative marijuana use was associated with higher forced
vital capacity, total lung capacity, functional residual capacity,
residual volume, and airway resistance, but there was no
significant change in the forced expiratory volume in 1 s, or
diffusing capacity. Tobacco smokers on the other hand, had
higher lung volumes suggestive of hyperinflation and in-
creased large airways resistance.
Marijuana and bullous lung disease
Althoughmarijuana has not been linked to the development of
chronic obstructive lung disease, asymmetrical bullous dis-
ease in the setting of normal chest X rays and lung function
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has been described. Johnson et al. [17] published a small case
series of four patients with significant exposure to cannabis
and limited tobacco use. They noted a form of bullous disease
with paraseptal distribution and a marked predisposition for
the upper lobes with little other parenchymal lung disease in
young male cannabis smokers. Hii et al. [18] reported similar
findings in a series of ten patients with new respiratory symp-
toms and one or more years of marijuana use. High-resolution
CT of the chest demonstrated variably sized, asymmetrical
emphysematous bullae in the upper and mid-lung zones.
Fiorelli et al. [19] have pointed to marijuana as a risk factor
for the development of bullous disease and pneumothorax.
His group has retrospectively evaluated 13 consecutive habit-
ual marijuana smokers who were referred for treatment of
spontaneous pneumothorax. In patients less than 35 years of
age, the incidence of bullae was higher in marijuana smokers,
defined as a lifetime total of at least 50 marijuana cigarettes,
compared to non marijuana smokers (7/10 vs. 3/10 patients,
respectively, p<0.05). Radiological findings on CTchest were
similar to those reported in the prior studies with upper lobe-
predominant paraseptal distribution of bullae. Chest x-rays,
however, showed no evidence of emphysema.
Furthermore, Beshay et al. [20] presented a retrospective
case series of 17 patients less than 40 years of age who
presented with spontaneous pneumothoraces and significant
upper lobe-predominant bullous emphysema. All but one
subject smoked marijuana daily for a mean of 8.8 years and
tobacco for 11.8 years. This has led to the term “marijuana
lung “or “bong lung” where patients typically develop large
peripheral paraseptal lung bullae and are predisposed to spon-
taneous pneumothoraces [21].
The exact mechanism of bulla formation in marijuana
smokers is not well understood. However it has been sug-
gested that development of bullous disease and subsequent
pneumothorax is related to inhalation techniques of marijuana
resulting in barotrauma. Common techniques involve deep
inhalation to hold smoke in the lung, performing a Valsalva
maneuver [7]. The average volume of puffs has been reported
to be 70 % larger (p<0.001) and the duration of puffs about
60 % longer (p<0.01 ) with a fourfold longer breath-holding
time while smoking marijuana as compared to tobacco use
[22]. This also resulted in inhalation of 2.8 to 3.3 times more
insoluble particulates (tar) with deposition of 32 % to 35 %
more particles compared to cigarette smoking, which may
contribute to significant inflammation and epithelial injury
[22].
Marijuana and pulmonary infections
Alveolar macrophages play a significant role in the biological
defense mechanisms of the lung via phagocytosis and destruc-
tion of pathogens. Therefore, impairment of this basic
function is likely to increase the incidence of infections. Based
on findings of rodent studies, Sherman et al. [23] designed a
study to investigate the effects of smoking marijuana on
human alveolar macrophages. They demonstrated that mari-
juana smoking decreased the ability of alveolar macrophages
to destroy ingested Candida albicans, but it did not result in
alteration of respiratory burst or phagocytosis. Baldwin et al.
[24] provided further evidence of impairment in alveolar
macrophage function due to cannabis use. Bronchoscopy
and BAL were performed on 56 subjects: 40 males and 16
females; mean age: 34.4±8.4 yr (including 22 non smokers,
10 marijuana smokers, 13 crack cocaine smokers, and 11
tobacco smokers). The alveolar macrophages were collected
for analysis. Macrophages from marijuana smokers were im-
paired in their ability to phagocytose Staphylococcus aureus
(p<0.01), kill both bacteria and tumor cells (p <0.01), and
produce cytokines.
However, clinical evidence of increased incidence of pul-
monary infections as a result of marijuana use is less robust
and largely anecdotal. A few case reports have documented
occurrence of aspergillosis related to marijuana use in immu-
nocompromised patients. Hamadeh et al. [25] reported a case
of fatal pulmonary aspergillosis in a 34-year-old bone marrow
transplant recipient with an extensive history of daily mari-
juana use prior to admission. Cescon et al. [26] also reported a
similar case of invasive pulmonary aspergillosis in a patient
with colorectal cancer who had been smoking marijuana for
the treatment of chemotherapy-induced nausea six weeks
prior to presentation. Case reports of marijuana-associated
aspergillosis have been documented in patients with rheuma-
toid arthritis on oral corticosteroids as well as a history of
Tetralogy of Fallot [27] .
In these case reports, the pulmonary infections have been
attributed to the contamination of marijuana by fungi and to
the fact that marijuana is smoked without a filter. This has
been confirmed by studies performed by Verweij et al. [28]
who cultured samples of tobacco and marijuana for mold.
Marijuana was found to be heavily contaminated with both
Penicillium species and Aspergillus fumigatus.
Marijuana inhalation techniques have also been linked to
the transmission of tuberculosis. Munckhof et al. [29] de-
scribed this phenomenon after identifying 149 contacts from
five index cases of pulmonary tuberculosis in Australia. In
these subjects, marijuana water pipe (bong) smoking was
common among both cases and contacts. Therefore sharing
a marijuana water pipe with an index case was identified as a
risk factor for acquisition of tuberculosis infection in this
subpopulation (OR 2.22, 95 % CI 0.96–5.17). Thu et al.
[30] also evaluated three index cases of cavitary pulmonary
disease and 34 identifiable positive contacts. A sixfold risk of
transmission of tuberculosis was identified among contacts
sharing a bong with an index case (odds ratio 6.5, confidence
interval 1.4–30.4, p=0.016).
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“Hotboxing” is another method of recreational marijuana
use reported to facilitate transmission of tuberculosis. This
involves multiple persons smoking inside a closed car to
repeatedly inhale exhaled smoke. Oeltmann and colleagues
[31] published a case series of 11 index cases with 121
potentially exposed contacts (54 friends, 67 other contacts).
Among those contacts who reported or were observed
“hotboxing”, 11 (79 %) of 14 who received a Tuberculin Skin
Test had a positive result. The association described between
marijuana inhalation and tuberculosis transmission remains
ambiguous, however, as it is not clear whether the increased
risk is due to closer proximity to an actively infected TB case
versus the result of impaired biological defense mechanisms
due to marijuana use.
Marijuana and lung cancer
A critical yet unresolved public health issue is whether can-
nabis smoking can increase the risk of lung cancer. Since
marijuana smoke contains many of the same chemicals as
tobacco smoke in addition to 60 cannabinoid compounds
[32] it is plausible to raise the hypothesis that it may be
carcinogenic. Several lines of evidence justify this concern:
marijuana and tobacco smoke contain many of the same
potent carcinogens and the condensate from marijuana smoke
is even more toxic than that from tobacco smoke [32]. Fur-
thermore, marijuana smoking results in greater delivery of tar
to the lungs because it is associated with deeper inhalation and
longer breath-holding times, and marijuana cigarettes are un-
filtered [7, 22]. In addition, studies looking at bronchial biop-
sies have demonstrated that marijuana users show inflamma-
tion of the airways, but also histological and molecular chang-
es indicative of precancerous changes, similar to those found
in tobacco smokers [12, 13, 33]. Marijuana is also widely
acknowledged to stimulate the mitogen-activated kinase
(MAPK) pathway, which is a major stimulant for develop-
mental and malignant cell growth. Exposure to cannabis was
associated with an increased incidence of acute
myelomonocytic leukemia (AMML) in the pediatric popula-
tion after in-utero exposure to cannabis [34].
Even though there is molecular, cellular, and histopatho-
logical evidence for a potential carcinogenic effect of mari-
juana, the epidemiologic studies yielded inconsistent results.
In a retrospective cohort study, 64,855 examinees aged 15–
49 years enrolled in the Kaiser Permanente health mainte-
nance organization in northern California were followed for
a mean length of 8.6 years [35]. Former and current users of
marijuana failed to show an increased incidence of cancers at
all sites after adjusting for tobacco use. Marijuana use was not
associated with common tobacco-related cancers or with can-
cers of the lung, colorectal, melanoma, breast, prostate, and
cervix. Among non-smokers of tobacco cigarettes, ever
having used marijuana was associated with an increased risk
of prostate cancer and a marginally increased risk of cervical
cancer. However, the study was limited by the relatively
young age of the subjects (average age was 48 years) and a
follow-up period that was not long enough to allow for the
development of cancer.
Also, a well designed population-based case–control study
in Washington state failed to find any increased risk for the
development of upper airway cancers in association with
marijuana use (RR 0.9; 99 % CI 0.6–1.3) or any trend towards
dose response in relation to the frequency and duration of use
[36].
Another large population-based case–control study of
1,212 cancer cases of the upper aero-digestive tract in Los
Angeles and 1,040 cancer-free controls also showed no pos-
itive association when adjusting for several confounders in-
cluding nicotine use [37].
However, a case–control study conducted by Aldington
et al. in New Zealand [38] included 79 cases of lung cancer
and 324 controls. Subjects and controls were <55 years old.
While marijuana smoking (lifetime use of more than 20 joints)
was not associated with a significant increased risk of lung
cancer, the subjects in the highest tertile of use (>10.5 joints/
year with one joint/year equivalent to smoking 365 joints or
filled pipes) had the highest risk RR 5.7 (95 % CI 1.5-21.6)
after adjustment for confounders. Using logistic regression,
the risk of lung cancer was estimated to increase by 8% ( 95%
CI 2–15 %) for each joint/year of cannabis smoked after
adjustment for confounding variables such as cigarette
smoking, occupation, family history, etc. In this study, the
association with lung cancer was found only in the third
tertile, which contained a small number of patients (14 pa-
tients) and there was no dose-dependent relationship noted.
Furthermore, Callaghan et al. [39], in a population-based
cohort study, examined 49,321 men aged 18–20 years old
(military conscripts) in Sweden recruited between 1969–
1979. The participants were tracked until 2009 (40 years) for
incident lung cancer outcome using several Swedish patient
registries. The study reported a twofold risk (hazard ratio 2.12,
95 % CI 1.08-4.14) of developing lung cancer over the 40-
year follow-up period after statistical adjustment for baseline
tobacco and alcohol use, co-existing respiratory conditions,
and socio-economical status.
Because case control studies yielded mixed results, several
authors presented pooled analyses of smaller studies.
Berthiller et al. [40] presented three case–control studies con-
ducted in Tunisia, Morocco, and Algeria, three areas of can-
nabis consumption and production. The study included 430
cases (all men) and 778 controls. All cannabis smokers were
tobacco users. The study found that there was a 2.4-fold
increase in the risk of lung cancer among ever cannabis
smokers compared to never users after adjustment for age,
tobacco smoking, and occupational exposure. The authors
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acknowledge the potential of residual confounding by tobacco
smoking (tobacco and marijuana are habitually smoked to-
gether in that part of the world).
In Tunisia, in a hospital-based case–control study, the risk
of lung cancer in prior cannabis users was studied in 149 new
lung cancer cases and 188 controls [41]. The odds ratio for the
past users of cannabis and lung cancer was 4.1 (95 % CI: 1.9-
9.0) after adjustment for age, tobacco use, and occupational
exposure. There was no clear dose–response relationship be-
tween the risk of lung cancer and the intensity or duration of
cannabis use. Because in Tunisia many cannabis smokers mix
cannabis with tobacco, tobacco may be a major confounder
for these results.
Mehra et al. [42] published a systematic review of the
impact of marijuana smoking on the development of prema-
lignant lung changes and lung cancer. 19 studies entered into
analysis from 186 initially identified. The authors found an
association of marijuana smoking with increased tar exposure,
alveolar macrophage tumoricidal dysfunction, increased oxi-
dative stress, and bronchial mucosa histopathologic abnormal-
ities compared to tobacco smokers and nonsmoking controls.
The study did not find a significant association between
marijuana use and lung cancer after adjusting for tobacco
use. The authors raise the question of methodologic deficien-
cies in the studies included in the analysis that may have
accounted for the results.
Zhang et al. [43] published a study which included 2,159
lung cancer cases and 2,985 controls pooled from six case-
controlled studies within the International Lung Cancer Con-
sortium. There was little evidence for an increased risk of lung
cancer among habitual or long-term cannabis smokers. The
authors however, mention that the possibility of potential
adverse effects of heavy consumption could not be excluded.
The epidemiological evidence for an association between
cannabis and lung cancer is limited and conflicting. Case
series have suggested a causative role for cannabis for lung
cancer in young adults. The case–control studies published to
date have suggested both the presence and absence of an
association, but these studies have been limited by the inabil-
ity to quantify use, confounded by combined cannabis and
tobacco or other substance use, or were undertaken in popu-
lations where cannabis use may have serious legal conse-
quences resulting in potential reporting bias and poor response
rates.
In addition, the interpretation of the epidemiological data is
further limited by the design of these studies: case series
represent uncontrolled observations fromwhich causality can-
not be inferred. Case–control studies, on the other hand,
establish associations, but this again does not represent cau-
sation. In some of the studies in which a relationship between
marijuana smoking and lung cancer was established, the as-
sociation was weak and there was no dose–response relation-
ship to strengthen the association.
Just as in the tobacco story, the long time lapse between
smokingmarijuana and the development of serious respiratory
complications attenuates the individual’s perception of risk.
As inconclusive as the epidemiological studies might be,
prudence should warn individuals that marijuana smoking
may result in serious short-term and long-term respiratory
complications, potentially as drastic as those caused by tobac-
co smoke.
Conclusions
The data presented, although not conclusive, suggest that in
our practice, we should scrutinize marijuana smoking with the
same diligence as we scrutinize tobacco use. The use of
marijuana should be assessed and documented at each visit,
both quantitatively and qualitatively, as precisely as possible,
and patients should be provided with counseling using the
same methods we use in treating tobacco addiction. The
medical literature so far does not support a role for routine
evaluation by pulmonary function tests or imaging studies,
and until more definitive data is available, we do not recom-
mend the regular use of these tests in the evaluation of habitual
marijuana smokers.
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